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Abstract 
Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) are 
recommended to receive oral anticoagulants (OAC) and concomitant antiplatelet agents 
followed by OAC monotherapy continued beyond a year after PCI. However, long-term 
prescription patterns of antithrombotic therapy in real-world clinical practice were not fully 
investigated. From the National Health Insurance Service database of Korea, we obtained 
records of patients with AF who underwent PCI between 2009 and 2013. Patients without 
repeated PCI or death within 2 years following the procedure were included. Prescription 
records of antithrombotic therapy including anticoagulants and antiplatelet agents were 
reviewed at 3-month intervals after discharge. We investigated 8,891 patients. At discharge, 
76.1% of the patients received dual antiplatelet therapy (DAPT) and only 17.1% received 
OAC. Although the proportion of patients receiving DAPT gradually decreased, >70% of 
patients received only antiplatelet agents (DAPT or single antiplatelet therapy [SAPT]) a year 
after PCI. During the 2-year follow-up, the proportion of patients receiving OAC remained 
<20%, and only 1.5% of the patients received OAC monotherapy a year after PCI. Female 
sex, previous myocardial infarction, peripheral vascular disease, and prescription of DAPT at 
discharge were associated with under-prescription of OAC a year after PCI. In conclusion, a 
significant proportion (76%) of patients with AF undergoing PCI were not prescribed OAC at 
discharge despite the high risk of stroke contrary to the current guidelines. Most patients 
continued to receive antiplatelet agents without OAC beyond the 1-year time-point after PCI. 
Keywords 
Atrial fibrillation, percutaneous coronary intervention, antiplatelet therapy, antithrombotic 
therapy 
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Oral anticoagulants (OAC) are essential for stroke prevention in atrial fibrillation (AF).
1, 2
 
Approximately 5–15% of patients with AF undergo percutaneous coronary intervention (PCI) 
with coronary stent implantation during their lifetime, which requires dual antiplatelet 
therapy (DAPT). Current guidelines recommend combination antithrombotic therapy with 
anticoagulants and antiplatelets for patients with AF after PCI.
3, 4
 Generally, the treatment 
comprises triple therapy with OAC and DAPT for the initial 1–6 months followed by dual 
therapy of OAC and an antiplatelet agent up to 12 months, and then subsequent OAC 
monotherapy for life-long anticoagulation. Nevertheless, previous studies have reported 
undertreatment with OAC in patients with AF
5-7
 and those undergoing PCI.
8-10
 However, 
limited data are available regarding long-term trends of antithrombotic therapy for patients 
with AF after PCI in real-world clinical practice. We investigated the 2-year trends of 
antithrombotic therapy in patients with AF undergoing PCI, using the Korean National Health 
Insurance database. 
 
Methods 
Data pertaining to the study population were obtained from the National Health 
Insurance Service claims database, which comprises inpatient and outpatient medical records, 
diagnostic codes, and claims for procedures and medication prescriptions.
11, 12
 The definitions 
of AF and comorbidities were validated in previous studies.
13-15
 Patients with diagnostic 
codes for AF based on the International Classification of Diseases, Tenth Revision, Clinical 
Modification (ICD-10-CM) codes I480–I484 and I489 during hospitalization or at ≥2 
outpatient clinics were diagnosed with AF. Those with diagnostic codes for mitral stenosis 
(I50, I52, and I59) or mechanical heart valves (Z952–Z954) were excluded. Procedure codes 
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for PCI (M6561, M6562, M6563, and M6564) were used to identify PCI events. Definitions 
of comorbidities are summarized in Supplementary Table 1. Hypertension and diabetes 
mellitus were defined based on diagnostic codes along with prescription claims for at least a 
single antihypertensive or antidiabetic drug, respectively. Congestive heart failure, stroke or 
systemic thromboembolism, myocardial infarction (MI), peripheral artery disease (PAD), and 
intracranial hemorrhage (ICH) were defined based on ICD-10-CM codes. CHA2DS2-VASc 
scores were calculated for each patient to assess individual stroke risk.
16 
 
We included patients with non-valvular AF who underwent PCI between January 
2009 and December 2013. Patients who died or underwent repeated PCI during the 2-year 
follow-up after the index PCI were excluded. We included only those with complete 2-year 
prescription records for antithrombotics after the index PCI. Eventually, medical records of 
8,891 patients were assessed for antithrombotic usage.  
We retrieved inpatient and outpatient prescription records (at 3-month intervals) of 
patients reporting antithrombotic usage including aspirin, clopidogrel, vitamin K antagonists 
(VKAs), and non-VKA oral anticoagulants (NOACs) from the time of the index PCI until the 
2-year follow-up time point. Patients were categorized as those without treatment, those 
receiving single antiplatelet therapy (SAPT, aspirin or clopidogrel), DAPT (aspirin and 
clopidogrel), OAC monotherapy (VKAs or NOACs), and OAC with antiplatelet agents 
(SAPT or DAPT). Edoxaban was introduced in Korea after 2016; thus, it was not included in 
the NOAC group in our analysis. Also, new generation P2Y12 inhibitors including prasugrel 
and ticagrelor were not included because they were not widely available in Korea during the 
study period.  
After categorizing patients based on the antithrombotic regimens at every 3-month 
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interval, 2-year temporal trends in prescription patterns were analyzed. To identify clinical 
factors that were independently associated with OAC use a year after PCI, multivariate 
logistic regression analysis was used after classifying the study population based on OAC 
prescriptions a year after PCI. This study was exempt from review by the Seoul National 
University Hospital Institutional Review Board (1706-160-863). Statistical significance was 
set at 2-tailed p values of <0.05. Statistical analysis was performed using the SAS software 
version 9.3 (SAS Institute, Cary, NC, USA). 
 
Results 
Of the total study population, 1,684 patients (18.9%) received OAC a year after PCI 
(OAC group). Table 1 shows the baseline characteristics of those with or without OAC a year 
after PCI. The OAC prescription rate was significantly higher in the OAC group than non-
OAC group (68.2% vs. 7.8%, p<0.001). The DAPT prescription rate in the OAC group was 
significantly lower than that in the non-OAC group (42.8% vs. 92.4%, p<0.001).  
After PCI, 76.1% of patients were prescribed DAPT at discharge whereas only 17.1% 
had OAC (Figure 1). Among those prescribed OAC at discharge, most patients received 
triple therapy (88.3%, n=1,343). During a year of follow-up, the proportion of patients 
receiving DAPT decreased from 76.1% to 45.9%, and that of patients receiving OAC 
decreased from 17.1% to 15.2%. Notably, the proportion of patients receiving triple therapy 
also decreased from 15.1% to 5.1%. A year after PCI, 73.1% of the total study population 
received only antiplatelet agents (SAPT or DAPT) without OAC. In the OAC group, only 9.9% 
of the patients were prescribed OAC monotherapy and 90.1% continued to receive 
combination antithrombotic regimens comprising SAPT (56.6%) or DAPT (33.5%) (Figure 
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2). The OAC prescription rate remained <20% throughout the follow-up. 
Old age (≥65 years), a history of heart failure, stroke, or systemic thromboembolism, 
and prescription of OAC at discharge were associated with a higher OAC prescription rate a 
year after PCI (Figure 3). Female sex, a history of MI or PAD, and prescription of DAPT 
without oral anticoagulation at discharge were associated with the underuse of OAC a year 
after PCI.  
 
Discussion 
Despite the recommendations of the current guidelines,
3, 4
 our study shows that most 
patients with AF (76.1%) did not receive anticoagulation therapy after PCI, and triple therapy 
was used in only 15.1% of patients. Several studies have reported under-prescription of triple 
therapy after PCI in patients with AF. In the CRUSADE registry, among the 1,648 patients 
with AF and non-ST segment elevation MI, only 27% were prescribed triple therapy after 
PCI.
8
 Lamberts et al. reported a population-based study of 12,165 Danish patients and 
observed that 15% of patients with AF received triple therapy at discharge.
9
 Similarly, a 
recent report analyzing data from an Asian registry showed that only 10% of patients with AF 
were prescribed triple therapy after PCI.
17
  
The discrepancy between the guidelines and real-world practice with respect to 
antithrombotic therapy after PCI could be attributed to the following: (1) DAPT after PCI is 
essential to avoid the risk of stent thrombosis.
18
 Thus, physicians tend to prioritize DAPT 
instead of oral anticoagulants after PCI. Interestingly, the treatment pattern of maintaining 
prolonged DAPT was also found in patients on anticoagulation as 33.5% of them still 
received triple therapy at a year after PCI; and (2) higher bleeding risks such as intracranial 
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hemorrhage following anticoagulation therapy in the Asian population may also discourage 
physicians to prescribe.
19, 20
  
During the 2-year follow-up, the proportion of patients receiving DAPT decreased 
over time. Notably, <20% of patients received OAC throughout the study period, although 
anticoagulation was clinically indicated in >95% of the non-OAC group a year after PCI. 
These results are contrary to current guidelines that recommend life-long OAC monotherapy 
beyond the 1-year time point after PCI.
3, 4 
 Choi et al. reported that among 629 patients with 
AF who underwent PCI and were prescribed DAPT, 96.1% and 76.3% continued aspirin and 
clopidogrel, respectively a year after PCI; however, the OAC prescription rate was 
significantly low throughout the follow-up (0.5%, 2.2%, and 4.9% at 6 months, 1, and 2 years, 
respectively).
17
 
Lamberts et al. have reported prescription patterns of antithrombotics in 8,700 
patients with AF and stable CAD defined as 12 months from an acute coronary event and 
showed that 62.7% patients (n=5,457) received only antiplatelet agents (SAPT or DAPT). 
The risk of all-cause death, coronary death, MI, and systemic thromboembolism in these 
patients was higher than that in patients who received OAC monotherapy.
21
 The prescription 
rate of DAPT a year after PCI was higher in our study (45.9% vs. 20.3%), which could be 
attributed to the difference in the proportion of patients with AF who underwent PCI (100% 
vs. 32.5%). We also observed that a history of cardiovascular disease including MI or PAD 
and the prescription rate of DAPT at discharge were independently associated with the 
underutilization of OAC a year after PCI. This result suggests that patients with AF in whom 
long-term antiplatelet therapy is clinically indicated are at an even higher risk of prolonged 
undertreatment with OAC. AF and concomitant CAD or PAD is associated with a 
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significantly high risk of adverse cardiovascular events; thus, optimal antithrombotic 
treatment (including OAC) is extremely important in these patients.
22
  
Current guidelines recommend life-long OAC monotherapy after the intensive phase 
of combination antithrombotic treatment.
3, 4
 Our study showed that a year after PCI, 33.3% of 
all patients receiving OAC continued to be prescribed triple therapy and only 9.9% were 
prescribed OAC monotherapy, which concurs with a previous report.
17
 Recently, the OAC-
ALONE trial compared the use of OAC alone with a combination of OAC and SAPT and 
evaluated the efficacy and safety of OAC monotherapy in patients with concomitant AF and 
stable CAD beyond a year after coronary stenting.
23
 Although no significant intergroup 
differences were observed in primary outcomes, the study was under-powered, and the results 
were inconclusive. Further prospective randomized trials are warranted to conclusively 
determine the optimal antithrombotic therapy regimen beyond a year after PCI in patients 
with AF. 
The limitations of our study are as follows: (1) Information regarding medication 
compliance among patients was unavailable in our study, which may affect the actual 
proportion of patients receiving different antithrombotic regimens. (2) Information regarding 
the bleeding risk factors in individual patients including a history of bleeding events or 
laboratory data such as time in therapeutic range in patients using VKAs were not included 
for analysis. Also, data on bleeding events observed during the 2-year follow-up were not 
included in the current analysis. (3) Data regarding the complexity of coronary lesions and 
the PCI procedure were also not included in our study because detailed information on 
coronary angiography, procedural records, and laboratory results is unavailable in the claims 
database. (4) Long-term efficacy and safety outcomes between groups receiving different 
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antithrombotics were not included in this study. Further studies are needed to evaluate the 
prognostic effect of various combinations of antithrombotic therapies in patients with AF 
undergoing PCI.  
In summary, a significant proportion (76%) of patients with AF undergoing PCI were not 
prescribed OAC therapy at discharge despite the high risk of stroke contrary to the current 
guidelines. Most of these patients continued to receive antiplatelet agents without OAC 
beyond the 1-year time point after PCI. 
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Figure legends 
Figure 1: Prescription patterns of antithrombotic therapy in patients with atrial 
fibrillation undergoing percutaneous coronary intervention 
Most patients (76.1%) were prescribed DAPT at discharge; however, only 17.1% of the 
patients received OAC at discharge. During the follow-up, the proportion of patients 
receiving OAC remained <20% of the total population.  
DAPT=dual antiplatelet therapy, OAC=oral anticoagulants, PCI=percutaneous coronary 
intervention, SAPT=single antiplatelet therapy 
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Figure 2: Prescription patterns of oral anticoagulants in patients with atrial fibrillation 
undergoing percutaneous coronary intervention 
Among patients receiving OAC, 88.2% received triple therapy at discharge, which gradually 
decreased thereafter. At the 1-year time point after PCI, 33.5% and 56.6% of the patients 
receiving OAC concomitantly received DAPT and SAPT respectively, whereas only 9.9% 
received OAC monotherapy. The OAC monotherapy prescription rate remained <20% during 
the follow-up.  
DAPT=dual antiplatelet therapy, OAC=oral anticoagulants, PCI=percutaneous coronary 
intervention, SAPT=single antiplatelet therapy 
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Figure 3: Factors associated with the oral anticoagulant prescription rate a year after 
percutaneous coronary intervention  
The OAC prescription rate at discharge, a history of congestive heart failure, stroke or 
systemic embolism, and old age were associated with higher OAC prescription rates. A 
history of myocardial infarction, peripheral artery disease, female sex, and the DAPT 
prescription rate at discharge were related to the underutilization of OAC a year after PCI.  
DAPT=dual antiplatelet therapy, OAC=oral anticoagulants, PCI=percutaneous coronary 
intervention, SAPT=single antiplatelet therapy 
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Table 1. Baseline characteristics of patients based on oral anticoagulant prescriptions 
  
1-year after Percutaneous Coronary 
Intervention 
Variable 
No Oral 
Anticoagulants 
(N=7,207) 
Oral 
Anticoagulants 
(N=1,684) 
P 
value 
Age (years) 68.7±9.5 69.4±8.3 0.013 
Age >65 years 5,066 (70.3%) 1,275 (75.7%) 
<0.00
1 
Men 4,421 (61.3%) 1,160 (68.9%) 
<0.00
1 
Diabetes Mellitus 2,740 (38.0%) 678 (40.3%) 0.089 
Hypertension* 6,332 (87.9%) 1,477 (87.7%) 0.864 
Dyslipidemia
†
 6,000 (83.3%) 1,342 (79.7%) 
<0.00
1 
Congestive Heart Failure 2,588 (35.9%) 812 (48.2%) 
<0.00
1 
Myocardial Infarction 2,256 (31.3%) 479 (28.4%) 0.022 
Previous Percutaneous Coronary 
Intervention 
716 (9.9%) 131 (8.4%) 0.051 
Peripheral Vascular Disease 1,764 (24.5%) 355 (21.1%) 0.003 
Stroke or Systemic Thromboembolism 1,918 (26.6%) 675 (40.1%) 
< 
0.001 
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Intracranial Hemorrhage 257 (3.6%) 71 (4.2%) 0.203 
CHA2DS2-VASc Score 4.4±1.9 4.7±1.8 
<0.00
1 
0–1 352 (4.9%) 50 (3.0%) 
<0.00
1 
2 ≤ 6,797 (95.0%) 1,631 (97.0%) 
 
Oral Anticoagulants at Discharge 564 (7.8%) 1,149 (68.2%) 
<0.00
1 
Dual Antiplatelet Therapy at 
Discharge 
6,661 (92.4%) 721 (42.8%) 
<0.00
1 
Values are presented as numbers (percentage) unless otherwise indicated. 
*Defined as patients with diagnostic code (the International Classification of Diseases, Tenth 
Revision, Clinical Modification [ICD-10-CM] code) of I10-I13, I15; and minimum 1 
prescription of anti-hypertensive drug (thiazide, loop diuretics, aldosterone antagonist, alpha-
/beta-blocker, calcium-channel blocker, angiotensin-converting enzyme inhibitor, angiotensin 
II receptor blocker). 
†
Defined as
 
patients with diagnostic code (ICD-10-CM) of E78 
 
